Image

Neuropsychological Assessment of Remediation for Cognitive Impairments in Schizophrenia

Neuropsychological Assessment of Remediation for Cognitive Impairments in Schizophrenia

Recruiting
18-60 years
All
Phase N/A

Powered by AI

Overview

This study evaluates the effect of a cognitive remediation program on neurocognitive, social cognitive and metacognitive functions designed for patients living with a schizophrenia spectrum disorder.

Description

Evaluation of the specific therapeutic efficacy of the ecological cognitive remediation program for schizophrenia spectrum disorder [ECo-Sz] on neurocognitive deficits, social cognition deficits and metacognition deficits of patients with a schizophrenia spectrum disorder.

In this double-blind (patients, outcomes assessors) controlled randomized trial the investigators compare patients receiving Ecological Cognitive training program for schizophrenia spectrum disorder [ECo-Sz] to patients benefiting from recovery-oriented therapy [ThOR]. Patients are treated for two months and monitored for four months.

Eligibility

Inclusion Criteria:

  • Schizophrenia Disorder diagnosis, according to Diagnostic and Statistical Manual of mental disorders - Fifth edition (DSM-V) - Patient stabilized in terms of positive and negative symptomatology (absence or presence of weak positive and negative symptoms)
  • Positive and Negative stable symptoms (no or few positive and negative symptoms)
  • Stable and effective minimum dose of medication (antipsychotic) for the last three months
  • Cognitive complaint expressed by the patient
  • Informed consent form read, initialed and signed
  • Understanding of spoken and read French
  • Patient registered on the social welfare system

Exclusion Criteria:

  • Other diagnosis at the forefront than Schizophrenia of the DSM-V
  • Medical history neurological disorder resulting in hospitalization
  • Acute episode in the last three month
  • Somatic disorders resulting in cognitive impairment
  • Engagement in a research protocol either currently or over the last month
  • Neuropsychological assessment evaluation during the last six month
  • Patients under the protection of a conservator (simple or reinforced)
  • Individuals in vulnerable circumstances

Study details
    Schizophrenic Disorders

NCT04608032

Centre hospitalier de Ville-Evrard, France

16 February 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.